Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

COX-2 inhibitors under study at Abbott

Jan. 8, 1998

Chiroscience discloses new MMP/TNF inhibitors

Jan. 7, 1998

Anika files for U.S. approval of osteoarthritis Rx

Jan. 5, 1998

COX-2 inhibitors reported by UPSA

Jan. 5, 1998

VX-740 advances in preclinical studies

Jan. 2, 1998

UPSA claims new COX-2 inhibitors for inflammation, pain and other disorders

Dec. 31, 1997

FDA approves Arthrotec, a new arthritis medication with NSAID efficacy and improved GI safety

Dec. 30, 1997

New antiinflammatory compounds disclosed by Glycomed

Dec. 30, 1997

Alexion files IND for C5 inhibitor treatment for rheumatoid arthritis

Dec. 29, 1997

Phase IIb trial of TCR vaccine for rheumatoid arthritis begins

Dec. 29, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...